Company news

Iovance Biotherapeutics, Inc. news in 2025

Iovance Biotherapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

November 6, 2025

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

November 3, 2025

Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025

October 23, 2025

Iovance Biotherapeutics to Present at Upcoming Conferences

August 29, 2025

Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

August 18, 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

August 7, 2025

Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025

July 24, 2025

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

July 15, 2025

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

July 14, 2025

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy

July 10, 2025

Iovance Biotherapeutics to Present at Upcoming Conference

June 10, 2025

The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma

June 2, 2025

Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting

May 22, 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025

May 8, 2025

Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

May 2, 2025

Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

April 23, 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

February 27, 2025

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

February 18, 2025

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

February 9, 2025

Calls in 2025

Decks in 2025